169 related articles for article (PubMed ID: 31290003)
21. Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: Systematic review and network meta-analysis.
Ji X; Liang W; Lv G; Ding C; Lai H; Li L; Zeng Q; Lv B; Sheng L
Front Pharmacol; 2022; 13():933648. PubMed ID: 36091770
[No Abstract] [Full Text] [Related]
22. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Prognostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments: a Meta-Analysis and Systematic Review.
Zheng J; Cai J; Li H; Zeng K; He L; Fu H; Zhang J; Chen L; Yao J; Zhang Y; Yang Y
Cell Physiol Biochem; 2017; 44(3):967-981. PubMed ID: 29179180
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review.
Zhang X; Yang XR; Huang XW; Wang WM; Shi RY; Xu Y; Wang Z; Qiu SJ; Fan J; Zhou J
Hepatobiliary Pancreat Dis Int; 2012 Oct; 11(5):458-66. PubMed ID: 23060390
[TBL] [Abstract][Full Text] [Related]
24. [New Systemic Therapies for Advanced Hepatocellular Carcinoma].
Kim DY
Korean J Gastroenterol; 2019 Jan; 73(1):10-15. PubMed ID: 30690953
[TBL] [Abstract][Full Text] [Related]
25. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib.
Yang Y; Wen F; Li J; Zhang P; Yan W; Hao P; Xia F; Bi F; Li Q
Liver Int; 2015 Sep; 35(9):2147-54. PubMed ID: 25676812
[TBL] [Abstract][Full Text] [Related]
26. Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology.
Galle PR; Kudo M; Llovet JM; Finn RS; Karwal M; Pezet D; Kim TY; Yang TS; Lonardi S; Tomasek J; Phelip JM; Touchefeu Y; Koh SJ; Stirnimann G; Liang K; Ogburn KD; Wang C; Abada P; Widau RC; Zhu AX
Liver Int; 2021 Nov; 41(11):2759-2767. PubMed ID: 34173317
[TBL] [Abstract][Full Text] [Related]
27. Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Kawaoka T; Aikata H; Teraoka Y; Inagaki Y; Honda F; Hatooka M; Morio K; Morio R; Kobayashi T; Nagaoki Y; Nakahara T; Hiramatsu A; Tsuge M; Imamura M; Kawakami Y; Chayama K
Oncology; 2017; 92(6):335-346. PubMed ID: 28245484
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib.
Lim S; Han J; Kim GM; Han KH; Choi HJ
J Gastroenterol Hepatol; 2015 Jun; 30(6):1024-31. PubMed ID: 25611175
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
Bruix J; Cheng AL; Meinhardt G; Nakajima K; De Sanctis Y; Llovet J
J Hepatol; 2017 Nov; 67(5):999-1008. PubMed ID: 28687477
[TBL] [Abstract][Full Text] [Related]
30. Does dual infection by hepatitis B and C viruses play an important role in the pathogenesis of hepatocellular carcinoma in Japan?
Shiratori Y; Shiina S; Zhang PY; Ohno E; Okudaira T; Payawal DA; Ono-Nita SK; Imamura M; Kato N; Omata M
Cancer; 1997 Dec; 80(11):2060-7. PubMed ID: 9392327
[TBL] [Abstract][Full Text] [Related]
31. Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis.
Lehman EM; Wilson ML
Int J Cancer; 2009 Feb; 124(3):690-7. PubMed ID: 18973270
[TBL] [Abstract][Full Text] [Related]
32. Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials.
Casadei Gardini A; Puzzoni M; Montagnani F; Marisi G; Tamburini E; Cucchetti A; Solaini L; Foschi FG; Conti F; Ercolani G; Cascinu S; Scartozzi M
Onco Targets Ther; 2019; 12():2981-2988. PubMed ID: 31118665
[No Abstract] [Full Text] [Related]
33. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
Cho HJ; Kim SS; Nam JS; Oh MJ; Kang DR; Kim JK; Lee JH; Kim B; Yang MJ; Hwang JC; Lim SG; Shin SJ; Lee KM; Yoo BM; Lee KJ; Cho SW; Cheong JY
Cytokine; 2017 Jul; 95():118-125. PubMed ID: 28260649
[TBL] [Abstract][Full Text] [Related]
34. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
35. An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.
Peng S; Zhao Y; Xu F; Jia C; Xu Y; Dai C
PLoS One; 2014; 9(12):e112530. PubMed ID: 25460347
[TBL] [Abstract][Full Text] [Related]
36. The contribution of serum hepatitis B virus load in the carcinogenesis and prognosis of hepatocellular carcinoma: evidence from two meta-analyses.
Chen X; Wu F; Liu Y; Lou J; Zhu B; Zou L; Chen W; Gong J; Wang Y; Zhong R
Oncotarget; 2016 Aug; 7(31):49299-49309. PubMed ID: 27384478
[TBL] [Abstract][Full Text] [Related]
37. Prognostic role of diabetes mellitus in hepatocellular carcinoma patients after curative treatments: a meta-analysis.
Wang WM; Xu Y; Yang XR; Wang YH; Sun HX; Fan J
Hepatobiliary Pancreat Dis Int; 2011 Aug; 10(4):346-55. PubMed ID: 21813381
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy.
Yeo W; Mo FK; Chan SL; Leung NW; Hui P; Lam WY; Mok TS; Lam KC; Ho WM; Koh J; Tang JW; Chan AT; Chan PK
Hepatology; 2007 Jun; 45(6):1382-9. PubMed ID: 17539025
[TBL] [Abstract][Full Text] [Related]
39. Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014).
Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ
J Hepatol; 2016 Dec; 65(6):1086-1093. PubMed ID: 27569777
[TBL] [Abstract][Full Text] [Related]
40. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients.
Utsunomiya T; Shimada M; Kudo M; Ichida T; Matsui O; Izumi N; Matsuyama Y; Sakamoto M; Nakashima O; Ku Y; Takayama T; Kokudo N;
Ann Surg; 2015 Mar; 261(3):513-20. PubMed ID: 25072437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
